CORONAVIRUS patients at Basildon hospital and two others are taking part in a huge national clinical trial aimed at finding treatments for Covid-19.
Almost 170 patients, all with confirmed cases of Covid-19, at Basildon, Southend and Broomfield hospitals are joining 6,000 other patients across the country in the ‘Recovery Trial’.
There were 201 positive Covid-19 cases receiving treatment at the three hospitals, as of Friday afternoon (24 April).
The study is one of three clinical trials being given urgent priority status by England’s chief medical officer, Professor Chris Whitty.
The three hospitals are part of the Mid and South Essex Hospital Trust, and staff were given an update via email on Friday explaining the number of patients in the trial and the number who had been treated.
The email said: “Nearly 170 MSE patients are enrolled in a massive national clinical trial aimed at swiftly finding treatments for Covid-19.
“They join 6,000 patients from 155 sites across the UK taking part in the recovery trial.
“It is one of the three clinical trials being given urgent public health priority status by England’s chief medical officer, Professor Chris Whitty, and tests a range of treatments.”
The Recovery trial’s website www.recoverytrial.net lists the following information regarding the trial:
“A range of potential treatments have been suggested for Covid-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive.
“The Recovery Trial will begin by testing some of these suggested treatments:
Lopinavir-Ritonavir (commonly used to treat HIV)
Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
Hydroxychloroquine (related to an anti-malarial drug)
Azithromycin (a commonly used antibiotic)
“Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. The Recovery Trial team will constantly review information on new drugs and include promising ones in the trial.”